Clinical Trial

A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure the pharmacokinetics, safety, and tolerability of S-892216 (S-892216-PO) in participants with mild, moderate, or severe renal impairment not on dialysis, or renal impairment requiring hemodialysis (HD), and in participants with normal renal function.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-10-14; most recent amendment 2026-07-10.
Status change: Recruiting → Completed 2026-07-10
Status change: Not Yet Recruiting → Recruiting 2025-10-28
Trial Details
NCT Number NCT07217886
Lead Sponsor Shionogi
Collaborators: Biomedical Advanced Research and Development Authority
Conditions Renal Impairment
Enrollment 24 participants
Start Date 2025-10-16
Primary Completion 2026-02-13 (estimated)
Study Completion 2026-02-13 (estimated)
Updated on ClinicalTrials.gov 2026-07-13